The Unique CNS Benefit: Drs. Mouabbi and Birhiray explain why Neratinib stands apart as the only approved therapy in the extended adjuvant setting shown to cut brain metastases risk in HER2+ disease, backed by data from the ExteNET trial.
Neratinib: Unique Reduction of CNS Recurrence Risk in the Extended Adjuvant Setting
You may also like
Recommended Videos
